bms 202 (Bristol Myers)
86
Structured Review
Bristol Myers
bms 202
Bms 202, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms+202/202+bms/pm42162747-28-112-86
Average 86 stars, based on 1 article reviews
Bms 202, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms+202/202+bms/pm42162747-28-112-86
Average 86 stars, based on 1 article reviews
bms 202 - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Activity Assay:Article Title: Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy Article Snippet: .. Bristol-myers squibb (BMS) developed Article Title: Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy Article Snippet: .. The virtual screening results and corresponding activity data of the prioritized compounds are summarized in , with other:Article Title: Comparative druggability of PD-1/PD-L1 inhibitors (A56, HD10): Cross-species differences in PD-L1 exposure and efficacy Article Snippet: The PD-1/PD-L1 immune checkpoint plays a crucial role in tumor immune evasion, making it a prime target for cancer immunotherapy.. While small-molecule inhibitors have emerged as promising alternatives to monoclonal antibodies, differences in PD-L1 exposure between human and murine models present challenges in preclinical evaluation.. In this study, we investigate the cross-species druggability of two potent small-molecule inhibitors, A56 and HD10, by comparing their binding affinity, immune modulation, and anti-tumor efficacy in both human and mouse PDL1 models. Screening:Article Title: Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy Article Snippet: .. The virtual screening results and corresponding activity data of the prioritized compounds are summarized in , with Positive Control:Article Title: Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy Article Snippet: .. The virtual screening results and corresponding activity data of the prioritized compounds are summarized in , with HTRF Assay:Article Title: Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy Article Snippet: .. The virtual screening results and corresponding activity data of the prioritized compounds are summarized in , with Drug discovery:Article Title: New thiazole-biaryls as small molecule immunomodulators (SMIs) targeting PD-1/PD-L1 axis. Article Snippet: Immune Checkpoint Inhibitors (ICIs) targeting the PD-1/PD-L1 axis have improved the clinical outcomes and revolutionized oncology treatment.. However, monoclonal antibody (mAb)-based ICIs are limited by high production and treatment cost, poor oral bioavailability, limited tumor penetration, and immune-related adverse effects.. To address this, here we have designed, synthesized, and evaluated a series of new thiazole-biphenylcontaining small molecules (15a-j, 16a-n, and 17a-y) targeting the PD-1/PD-L1 interface. |
